Showing results (1801-1810 of 1,886) with videos related to

Sort By:
Pageof 189
Blood|September 22, 2023
Natural history study of patients with familial platelet disorder with associated myeloid malignancyLea Cunningham, Matthew Merguerian, Katherine R Calvo, et al.
JACC. Cardiovascular Interventions|August 18, 2022
Sex Difference in Outcomes Following Transcatheter Aortic Valve Replacement in Bicuspid Aortic StenosisJing-Jing He, Tian-Yuan Xiong, Yi-Jun Yao, et al.
Nature Genetics|May 29, 2007
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancerDavid J Hunter, Peter Kraft, Kevin B Jacobs, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 5, 2019
Evaluation of Rare and Common Variants from Suspected Familial or Sporadic Nasopharyngeal Carcinoma (NPC) Susceptibility Genes in Sporadic NPCZhiwei Liu, Alisa M Goldstein, Wan-Lun Hsu, et al.
Cell Reports. Medicine|December 5, 2025
An integrated language-vision foundation model for conversational diagnostics and triaging in primary eye careZhi Da Soh, Yang Bai, Kai Yu, et al.
Science Advances|February 12, 2025
Laboratory observation of ion drift acceleration via reflection off laser-produced magnetized collisionless shocksHui-Bo Tang, Yu-Fei Hao, Guang-Yue Hu, et al.
Plos Genetics|September 24, 2010
Identification of new genetic risk variants for type 2 diabetesXiao Ou Shu, Jirong Long, Qiuyin Cai, et al.
American Journal of Epidemiology|June 22, 2010
Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer CancersMarjorie L McCullough, Stephanie J Weinstein, D Michal Freedman, et al.
Cancer Discovery|June 4, 2023
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance MutationsVivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Journal of Medicinal Chemistry|June 5, 2026
Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2αArtur K Mailyan, Guillaume Mata, Joel W Beatty, et al.
Pageof 189